IHMA Europe Sàrl, 4 Route de la Corniche, 1066, Epalinges, Switzerland.
Eur J Clin Microbiol Infect Dis. 2011 Feb;30(2):173-9. doi: 10.1007/s10096-010-1066-0. Epub 2010 Oct 16.
As part of the worldwide Study for Monitoring Antimicrobial Resistance Trends (SMART), a total of 3,030 clinical isolates of gram-negative bacilli from intra-abdominal infections were collected from 43 hospital centres from 13 European countries during 2008. Of 51 species, the most commonly isolated species were Escherichia coli (49.3%), followed by Klebsiella pneumoniae (10.5%) and Pseudomonas aeruginosa (8.6%). Respectively, 17.9%, 11.6%, 5.5% and 4.5% of K. pneumoniae, E. coli, Proteus mirabilis and K. oxytoca were extended-spectrum beta-lactamase (ESBL)-positive. All isolates were tested using a panel of 12 antimicrobial agents, and susceptibilities were determined using European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints. The most active agents against the study isolates (including those producing ESBLs) were amikacin, ertapenem and imipenem. Overall, with the exception of the carbapenems, most agents exhibited dramatically reduced susceptibilities against ESBL-positive and multi-drug-resistant isolates.
作为全球监测抗菌药物耐药趋势（SMART）研究的一部分，2008 年期间，从欧洲 13 个国家的 43 家医院中心共收集了 3030 株腹腔感染的革兰氏阴性杆菌临床分离株。在 51 个种属中，最常见的分离株是大肠埃希菌（49.3%），其次是肺炎克雷伯菌（10.5%）和铜绿假单胞菌（8.6%）。分别有 17.9%、11.6%、5.5%和 4.5%的肺炎克雷伯菌、大肠埃希菌、奇异变形杆菌和催产克雷伯菌产超广谱β-内酰胺酶（ESBL）。所有分离株均使用 12 种抗菌药物进行了检测，并使用欧洲抗菌药物敏感性试验委员会（EUCAST）临床折点确定了敏感性。对研究分离株（包括产 ESBL 的分离株）最有效的药物是阿米卡星、厄他培南和亚胺培南。总体而言，除了碳青霉烯类药物外，大多数药物对产 ESBL 和多药耐药的分离株的敏感性显著降低。
